Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• Indian Oil Announced Q4 Earnings; Net Profit Plunges 49% 
• RVNL Shares Gain as JV Secures Project Worth Rs 438 Crore
• Granules Shares Gain 2% on USFDA Approval 
• Patanjali Foods Shares Slump 4% on Receiving Show Cause Notice 
• KEC International Shares Rally 6% on Securing Orders Worth Rs 1,036 crore

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.